| Literature DB >> 28910373 |
Roberto Lorbeer1, Holger Hetterich1, Ralf Strobl2, Anina Schafnitzel1, Hannah Patscheider1, Andreas Schindler1, Katharina Müller-Peltzer1, Wieland Sommer1, Annette Peters3,4,5, Christa Meisinger3,6, Margit Heier3,7, Wolfgang Rathmann8, Fabian Bamberg1,9, Eva Grill2,10,11.
Abstract
OBJECTIVE: We investigated the association between subclinical cardiovascular diseases assessed by MRI examination and symptoms of dizziness and vertigo in participants of a population-based sample.Entities:
Mesh:
Year: 2017 PMID: 28910373 PMCID: PMC5599022 DOI: 10.1371/journal.pone.0184858
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of the study sample according to lifetime prevalence of dizziness and vertigo.
| With dizziness and vertigo | Without dizziness and vertigo | p-value | |
|---|---|---|---|
| N = 121 | N = 279 | ||
| Age (years) | 58 (50–64) | 56 (48–64) | 0.372 |
| Men | 60 (49.6%) | 171 (61.3%) | 0.030 |
| Smoking status | 0.005 | ||
| Never-smoker | 54 (44.6%) | 92 (33.0%) | |
| Ex-smoker | 54 (44.6%) | 120 (43.0%) | |
| Current smoker | 13 (10.7%) | 67 (24.0%) | |
| BMI (kg/m2) | 27.1 (24.5–30.8) | 27.5 (24.8–30.9) | 0.927 |
| BSA (m2) | 1.9 (1.8–2.1) | 2.0 (1.8–2.1) | 0.045 |
| Waist circumference (cm) | 98 (89–107) | 100 (90–107) | 0.553 |
| Systolic BP (mmHg) | 120 (109–131) | 121 (108–131) | 0.861 |
| Diastolic BP (mmHg) | 75 (69–81) | 75 (68–81) | 0.932 |
| Hypertension | 39 (32.2%) | 97 (34.8%) | 0.623 |
| Diabetic status | 0.305 | ||
| Normal glucose metabolism | 79 (65.3%) | 164 (58.8%) | |
| Prediabetes | 25 (20.7%) | 78 (28.0%) | |
| Diabetes | 17 (14.1%) | 37 (13.3%) | |
| HbA1c (%) | 5.4 (5.2–5.6) | 5.4 (5.3–5.7) | 0.360 |
| Glucose (mg/dl) | 98 (91–109) | 99 (93–110) | 0.630 |
| HDL-C (mg/dl) | 62 (49–75) | 59 (48–72) | 0.172 |
| LDL-C (mg/dl) | 139 (120–162) | 137 (114–160) | 0.620 |
| Total cholesterol (mg/dl) | 220 (193–248) | 214 (190–239) | 0.253 |
Data are given as number (percentage) or median (25th and 75th percentile).
p-values from χ2 test or Wilcoxon rank-sum test
BMI, body mass index; BSA, body surface area; BP, blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density-lipoprotein cholesterol; LDL-C, low-density-lipoprotein cholesterol.
Cardiovascular MRI characteristics of the study sample according to lifetime prevalence of dizziness and vertigo.
| MRI parameter | With dizziness and vertigo | Without dizziness and vertigo | p-value |
|---|---|---|---|
| End-diastolic volume (ml) | 128 (103–152) | 124 (108–149) | 0.702 |
| End-systolic volume (ml) | 38 (29–51) | 36 (29–49) | 0.710 |
| Stroke volume (ml) | 87 (75–103) | 87 (74–101) | 0.963 |
| Ejection Fraction (%) | 71 (64–74) | 70 (64–75) | 0.756 |
| Myocardial mass, diastolic (g) | 134 (115–164) | 143 (119–161) | 0.287 |
| Myocardial mass, systolic (g) | 137 (112–163) | 144 (118–167) | 0.192 |
| End-diastolic volume (ml) | 159 (129–186) | 167 (139–193) | 0.115 |
| End-systolic volume (ml) | 76 (56–94) | 77 (61–95) | 0.387 |
| Stroke volume (ml) | 85 (70–97) | 87 (73–100) | 0.311 |
| Ejection Fraction (%) | 53 (48–58) | 53 (48–58) | 0.773 |
| Presence of plaque (AHA lesion type III-VII) (%) | 12 (13.5%) | 43 (24.6%) | 0.036 |
| Normalized wall index | 0.43 (0.40–0.45) | 0.42 (0.40–0.45) | 0.689 |
| Mean wall thickness (mm) | 0.73 (0.68–0.80) | 0.73 (0.69–0.79) | 0.853 |
| Presence of white matter lesions (%) | 16 (13.7%) | 30 (11.2%) | 0.482 |
| Presence of cerebral microbleeds (%) | 18 (15.4%) | 31 (11.7%) | 0.314 |
Data are given as number (percentage) or median (25th and 75th percentile).
p-values from χ2 test or Wilcoxon rank-sum test
Association of MRI determined cardiovascular measurements with dizziness and vertigo.
| MRI parameter | Dizziness and vertigo | |||
|---|---|---|---|---|
| Lifetime prevalence | 12-month prevalence | |||
| Odds Ratio | p-value | Odds Ratio | p-value | |
| End-diastolic volume/BSA (ml/m2) | 1.13 (0.89–1.44) | 0.307 | 0.99 (0.75–1.32) | 0.957 |
| End-systolic volume/BSA (ml/m2) | 1.14 (0.91–1.44) | 0.249 | 1.12 (0.87–1.45) | 0.372 |
| Stroke volume/ BSA (ml/m2) | 1.06 (0.84–1.35) | 0.615 | 0.87 (0.65–1.16) | 0.341 |
| Ejection Fraction (%) | 0.93 (0.74–1.17) | 0.560 | 0.89 (0.69–1.15) | 0.371 |
| Myocardial mass, diastolic/BSA (g/m2) | 1.18 (0.91–1.53) | 0.221 | 1.10 (0.81–1.51) | 0.536 |
| Myocardial mass, systolic/BSA (g/m2) | 1.11 (0.84–1.46) | 0.482 | 1.07 (0.77–1.50) | 0.688 |
| End-diastolic volume/BSA (ml/m2) | 0.94 (0.72–1.23) | 0.666 | 0.86 (0.62–1.18) | 0.343 |
| End-systolic volume/BSA (ml/m2) | 0.99 (0.77–1.28) | 0.957 | 0.98 (0.72–1.32) | 0.876 |
| Stroke volume/ BSA (ml/m2) | 0.94 (0.73–1.22) | 0.635 | 0.80 (0.58–1.10) | 0.166 |
| Ejection Fraction (%) | 0.99 (0.76–1.29) | 0.944 | 0.89 (0.65–1.22) | 0.462 |
| Presence of plaque (AHA lesion type III-VII) (%) | 0.50 (0.24–1.02) | 0.058 | 0.44 (0.17–1.12) | 0.085 |
| Normalized wall index | 1.03 (0.79–1.35) | 0.810 | 1.02 (0.75–1.39) | 0.916 |
| Mean wall thickness (mm) | 1.07 (0.81–1.4) | 0.645 | 1.07 (0.77–1.47) | 0.691 |
| Presence of WML (%) | 1.26 (0.63–2.49) | 0.512 | 1.71 (0.80–3.67) | 0.169 |
| Presence of CMB (%) | 1.40 (0.72–2.70) | 0.319 | 1.48 (0.70–3.15) | 0.304 |
Data are from logistic regression, adjusted for age, sex, BMI, hypertension and diabetes mellitus.
* SD increment for continuous variables.
BSA, body surface area; WML, white matter lesions; CMB, cerebral microbleeds.
Fig 1Prevalence of 12-month dizziness and vertigo according to groups with and without white matter lesions.
In women and men (Panel A) and in persons with normal glucose metabolism and in prediabetic or diabetic persons (Panel B).
Fig 2Prevalence of 12-month dizziness and vertigo according to groups with and without cerebral microbleeds.
In women and men (Panel A) and in persons with normal glucose metabolism and in prediabetic or diabetic persons (Panel B).